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Introduction/Case

In anesthesia one of the
specialty areas would be the
airway and angioedema affects
the airway even sometimes to
the point of compromising the
airway to the point of
emergency interventions.
According to (“Angioedema Immunology; Allergic
Disorders,” n.d.) “Angioedema is
edema of the deep dermis and
subcutaneous tissue” “due to
increased vascular permeability
include the following mast-cell,
bradykinin and complement
mediators”. While Aceinhibitors are well known for
use to combat hypertension
they are also according to
(“Angiotensin-converting
enzyme (ACE) inhibitors,” n.d.)
used for “Coronary artery
disease, Heart failure, Diabetes,
Kidney disease, MI, Scleroderma
and Migraines”. Which makes
there treatment field more
widely used than many truly
understand. This makes the risk
of ACE-inhibitor induced
angioedema even greater with
such a wide range of patients.
While many causes of
angioedema are known
According to (“ACE inhibitorinduced angioedema UpToDate,” n.d.) “Angiotensinconverting enzyme (ACE)
inhibitors are the leading cause
of drug-induced angioedema in
the United States because they
are so widely prescribed”.

Sings and
Symptoms
The specific Signs and
symptoms according to
(“Angioedema - Immunology;
Allergic Disorders,” n.d.)
“edema is often asymmetric
and mildly painful. It often
involves the face, lips, and/or
tongue and may also occur on
the back of hands or feet or on
the genitals. Edema of the
upper airways may cause
respiratory distress and stridor;
the stridor may be mistaken for
asthma. The airways may be
completely obstructed. Edema
of the intestines may cause
nausea, vomiting, colicky
abdominal pain, and/or
diarrhea.”

(“Angioedema - Pharmacy
and Drugs,” n.d.)

(“Learn It,” n.d.)

Significance of Patho

Conclusion

Implications for Nursing

Underlying Patho
The following article describes
the process of the
Pathophysiology concept behind
Ace-inhibitor Angioedema
(Campo, Fernandez, Canto, &
Mayorga, 2013) “ACEI-AAG is due
to excessive accumulation of
bradykinin. The reason that only
a small fraction of patients
treated with ACE inhibitors
develop ACEI-AAG may relate to
genetic variations in bradykinin
metabolism. During treatment
with ACE inhibitors, various
alternative enzymatic pathways
for metabolism of bradykinin
become critical (e.g. plasma
aminopeptidase P). Individuals
with lower activity of these
alternative clearance pathways
may be at increased risk of
bradykinin accumulation and
ACEI-AAG.” While many may
wonder what Bradykinins role is
according to (“Angioedema,”
n.d.) “Plasma globulins called
kininogens release bradykinin
and cause vascular permeability
and Inhibition of ACE hinders the
degradation of bradykinin”

The pathophysiologic concepts are significant in many ways such a
treatment pathway and understanding risks involved. While many
treatment options are different they all share a common goal which is
to stop the progression of airway compromise. The key is choosing
the correct treatment plan in order to stop the process that is
occurring whether treating for Mast cell reaction, Bradykinin and
complement, Acute, chronic, hereditary or acquired angioedema. The
chosen treatment pathway can have great success or end with the
death of a patient if the wrong treatment guidelines are chosen.
While this can be exemplified by the example of treating a mast cell
reaction as a chronic condition which could compromise the patients
airway resulting in death or a tracheostomy.

(Src="https://I2.wp.com/Emcrit.org/Wp-Content/Uploads/Gravatar/FarkasJosh-Wc.jpg?w=80, Pulmonary, & Vermont, 2015)

While a nurse in advanced
practice in any setting must be
vigilant of this lurking threat to
the most important aspect of
life we call the airway the CRNA
must be extra vigilant of the
medications there patient is
taking whether the ACEinhibitor is new or a lifelong
medication. The advanced
practice nurse must know not
only what type of Angioedema
the patient is suffering from but
how to properly treat the
specific aliment the patient is
experiencing. Also we must be
able to bring a calm
compassionate manner to the
bedside of these patients who
are fearful, anxious, and fighting
for their airway in some cases.
The hard choice must be made
.
to take
control of the airway if
needed in some cases whether
that be intubation or
tracheostomy placement but
this is the choice that lies heavy
upon the advanced practice
nurse.

The potential of adverse
effects from ACE-inhibitors
should be heavily taken into
consideration when reviewing
the patient record and when
prescribing this medication. The
dangers of not being prepared
to deal with this potential life
threating event could result in
catastrophic consequences for
the patient. The CRNA or
Advanced practice nurse must
be ready to identify the
different causative factors and
treat them in accordance with
the proper treatment protocol.
While ACE-inhibitors are a
wonderful and useful drug that
can treat multiple disease
processes the risk must always
way heavy on the minds of
those treating patients taking
these class of medications. The
goal should be not only to
spread awareness but
knowledge that expressly deals
with the identification and
treatment of angioedema.

Treatment
According to (“Angioedema - Immunology; Allergic Disorders,”
n.d.) “For bradykinin-mediated angioedema, epinephrine,
corticosteroids, and antihistamines have not been shown to be
effective. Angioedema due to ACE inhibitor use usually resolves about
24 to 48 h after stopping the drug. If symptoms are severe,
progressing, or refractory, treatments used for hereditary or acquired
angioedema can be tried. They include fresh frozen plasma, C1
inhibitor concentrate, and possibly ecallantide (which inhibits plasma
kallikrein, required for the generation of bradykinin)
and icatibant (which blocks bradykinin)”. Also according to
(“Angioedema - Immunology; Allergic Disorders,” n.d.) “Securing an
airway is the highest priority” obviously when the patient can no
longer keep their own airway secure.

(Juraga, n.d.)
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